Sutro Biopharma, Inc. 310 Utah Ave. Suite 150, South San Francisco, California 94080, USA.
Biotechnol Bioeng. 2011 Jul;108(7):1570-8. doi: 10.1002/bit.23103. Epub 2011 Mar 31.
Engineering robust protein production and purification of correctly folded biotherapeutic proteins in cell-based systems is often challenging due to the requirements for maintaining complex cellular networks for cell viability and the need to develop associated downstream processes that reproducibly yield biopharmaceutical products with high product quality. Here, we present an alternative Escherichia coli-based open cell-free synthesis (OCFS) system that is optimized for predictable high-yield protein synthesis and folding at any scale with straightforward downstream purification processes. We describe how the linear scalability of OCFS allows rapid process optimization of parameters affecting extract activation, gene sequence optimization, and redox folding conditions for disulfide bond formation at microliter scales. Efficient and predictable high-level protein production can then be achieved using batch processes in standard bioreactors. We show how a fully bioactive protein produced by OCFS from optimized frozen extract can be purified directly using a streamlined purification process that yields a biologically active cytokine, human granulocyte-macrophage colony-stimulating factor, produced at titers of 700 mg/L in 10 h. These results represent a milestone for in vitro protein synthesis, with potential for the cGMP production of disulfide-bonded biotherapeutic proteins.
在基于细胞的系统中,工程化具有稳健性的蛋白质生产和正确折叠的治疗性生物蛋白的纯化通常具有挑战性,因为需要维持复杂的细胞网络以保持细胞活力,并且需要开发相关的下游工艺,以可重复地生产具有高产品质量的生物制药产品。在这里,我们提出了一种替代的基于大肠杆菌的开放细胞游离合成(OCFS)系统,该系统经过优化,可在任何规模下进行可预测的高产蛋白质合成和折叠,并具有简单的下游纯化工艺。我们描述了 OCFS 的线性可扩展性如何允许在微升规模上快速优化影响提取物激活、基因序列优化和形成二硫键的氧化还原折叠条件的参数。然后可以使用标准生物反应器中的批量工艺来实现高效且可预测的高水平蛋白质生产。我们展示了如何使用 OCFS 从优化的冷冻提取物中生产的全生物活性蛋白质,然后使用简化的纯化工艺直接进行纯化,该工艺可产生生物活性细胞因子,人粒细胞-巨噬细胞集落刺激因子,在 10 小时内以 700mg/L 的滴度生产。这些结果代表了体外蛋白质合成的一个里程碑,具有生产二硫键结合的治疗性生物蛋白的 cGMP 生产的潜力。